Table 1 Patients’ characteristics (25 allo-HSCT patients)
| Â | Total |
|---|---|
n = 25 | |
Demographics | |
 Sex (male), n (%) | 16 (64.0) |
 Age, median (IQR) | 58.0 (25.0) |
Allo-HSCT considered in the analysis, n (%) | |
 First | 23 (92.0) |
 Second | 2 (8.0) |
Transplant source, n (%) | |
 Bone marrow | 5 (20) |
 Peripheral blood cells | 20 (80) |
Underlying disease, n (%) | |
 Acute myeloid leukemia | 10 (40.0) |
 Lymphoid malignancy | 6 (24.0) |
 MDS/MDPS | 3 (12.0) |
 Acute lymphoid leukemia | 2 (8.0) |
 Othera | 4 (16.0) |
Risk score, n (%) | |
 Low | 0 (0) |
 Intermediate | 18 (72.0) |
 High | 7 (28.0) |
Donor sex, M, n (%) | 7 (28.0) |
Donor age, median (IQR) | 36 (16.5) |
Donor match, n (%) | |
 Donor-related | 10 (40.0) |
CMV donor/recipient constellation, n (%) | |
 +/+ | 12 (48.0) |
 −/+ | 1 (4.0) |
 +/− | 7 (28.0) |
 −/− | 5 (20.0) |
CMV prophylaxis, n (%) | 1 (4.0) |
Conditioning, n (%) | |
 Myeloablative conditioning | 5 (20.0) |
GvHD prophylaxis, n (%) | |
 Calcineurin inhibitor | 24 (96.0) |
 Mycophenolate mofetil | 17 (68.0) |
 Methotrexate | 7 (28.0) |
GvHD organ, n (%) | |
 Digestive tract | 17 (68.0) |
 Skin | 15 (60.0) |
 Mouth | 4 (16.0) |
 Liver | 7 (28.0) |
 Lung | 5 (20.0) |
 Eyes | 2 (8.0) |
 Musculoskeletal | 1 (4.0) |
GvHD grade or severity, n (%) | |
 Grade | |
  2 | 9 (36.0) |
  3 | 3 (12.0) |
  4 | 6 (24.0) |
 Moderate | 6 (24.0) |
 Severe | 7 (28.0) |
GvHD treatment, n (%) | |
 Corticosteroids | 24 (96.0) |
 Ruxolitinib | 22 (88.0) |
 Calcineurin inhibitor | 21 (84.0) |
 Mycophenolate mofetil | 12 (48.0) |
 Photopheresis | 12 (48.0) |
 Budenoside | 5 (20.0) |
 Sirolimus | 3 (12.0) |
 Tocilizumab | 2 (8.0) |
 Otherb | 6 (24.0) |
Death, n (%) | 15 (60.0) |
 Median delay from allo-HSCT, months (IQR) | 11.2 (15.8) |